PF-739, with the CAS number 1852452-14-2, is a small molecule that has garnered attention in the field of medicinal chemistry, particularly for its role as a selective inhibitor of the protein kinase PAK4 (p21-activated kinase 4). This compound is characterized by its ability to interfere with cellular signaling pathways that are often dysregulated in various cancers, making it a potential candidate for cancer therapeutics. PF-739 exhibits a specific binding affinity for PAK4, which is involved in processes such as cell proliferation and survival. The compound's structure typically includes functional groups that enhance its solubility and bioavailability, which are crucial for its efficacy in biological systems. Additionally, PF-739 has been studied for its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), which are essential for determining its suitability for further development in clinical settings. Overall, PF-739 represents a promising avenue for targeted cancer therapy, although further research is needed to fully elucidate its therapeutic potential and safety profile.

PF-739 is an AMPK agonist. It has been shown to activate AMPK in hepatocytes and skeletal muscle.

PF-739

1852452-14-2: PF-739, with the CAS number 1852452-14-2, is a small molecule that has garnered attention in the field of medicinal chemistry, particularly for its role as a selective inhibitor of the protein kinase PAK4 (p21-activated kinase 4). This compound is characterized by its ability to interfere with cellular signaling pathways that are often dysregulated in various cancers, making it a potential candidate for cancer therapeutics. PF-739 exhibits a specific binding affinity for PAK4, which is involved in processes such as cell proliferation and survival. The compound's structure typically includes functional groups that enhance its solubility and bioavailability, which are crucial for its efficacy in biological systems. Additionally, PF-739 has been studied for its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), which are essential for determining its suitability for further development in clinical settings. Overall, PF-739 represents a promising avenue for targeted cancer therapy, although further research is needed to fully elucidate its therapeutic potential and safety profile.

(3R,3aR,6R,6aR)-6-((6-Chloro-5-(4-(1-(hydroxymethyl)cyclopropyl)phenyl)-1H-benzo[d]imidazol-2-yl)oxy)hexahydrofuro[3,2-b]furan-3-ol

PF-739 is an AMPK agonist that has been shown to activate AMPK in hepatocytes and skeletal muscle.

CAS 1852452-14-2

PF-739

(3R,3aR,6R,6aR)-6-((6-Chloro-5-(4-(1-(hydroxymethyl)cyclopropyl)phenyl)-1H-benzo[d]imidazol-2-yl)oxy)hexahydrofuro[3,2-b]furan-3-ol

Ref: 54-OR1062991

PF-739

Ref: TM-T24628